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Background: Necrotizing enterocolitis (NEC) is a disease in neonates, often resulting in death or serious medical or
neurodevelopmental complications. The rate of NEC is highest in the smallest babies and many efforts have been
tried to reduce the rate of NEC. In neonates born below 1500 grams, the rate of NEC has been significantly reduced
with the use of various probiotics. This study examines the impact of routine use of a probiotic, Lactobacillus reuteri
DSM 17938 (BioGaiaW), on the rate of NEC in neonates at highest risk for developing NEC, those with birth weight
≤1000 grams.
Methods: This is a retrospective cohort study comparing the rates of NEC in neonates with birth weight≤ 1000
grams. The groups are separated into those neonates born from January 2004 to June 30, 2009, before introduction
of L. reuteri, and neonates born July 2009 through April 2011 who received routine L. reuteri prophylaxis. The chart
review study was approved by our institutional review board and exempted from informed consent.
Neonates were excluded if they died or were transferred within the first week of life. The remainder were
categorized as having no NEC, medical NEC, surgical NEC, or NEC associated death. Since no major changes
occurred in our NICU practice in recent years, and the introduction of L. reuteri as routine prophylaxis was abrupt,
we attributed the post-probiotic changes to the introduction of this new therapy. Rates of NEC were compared
using Chi square analysis with Fisher exact t-test.
Results: Medical records for 311 neonates were reviewed, 232 before- and 79 after-introduction of L. reuteri
prophylaxis. The incidence of NEC was significantly lower in the neonates who received L. reuteri (2 of 79 neonates
[2.5%] versus 35 of 232 untreated neonates [15.1%]). Rates of late-onset gram-negative or fungal infections (22.8
versus 31%) were not statistically different between treated and untreated groups. No adverse events related to use
of L reuteri were noted.
Conclusions: Prophylactic initiation of L. reuteri as a probiotic for prevention of necrotizing enterocolitis resulted in
a statistically significant benefit, with avoidance of 1 NEC case for every 8 patients given prophylaxis.
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Probiotics are live microorganisms that provide benefi-
cial effects when administered to humans. Use of pro-
biotics in the neonatal intensive care unit (NICU) has
been associated with decreased mortality and decreased
severity and/or incidence of necrotizing enterocolitis
(NEC) [1-5]. NEC is viewed a multifactorial disease with
inflammation, destruction and bacterial invasion of the
gut wall. Proponents of probiotic use argue that control
of the bacterial flora in the gut can markedly affect NEC
risk. Meta-analyses have provided further support for
the value of these products [6,7]. However, other authors
caution against routine use of probiotics, citing concerns
with product quality and possible adverse effects [8,9].
Also questions remain about which bacterial strain(s)
would be most beneficial. This places each NICU in the
position of deciding whether they deem the evidence
sufficient to selectively or routinely utilize probiotics in
their practice. If they elect to employ probiotics as a
NEC prevention strategy, each NICU must also decide
which probiotic product to use. Since the bulk of the
evidence focuses on using probiotics in neonates
born < 1,500 grams [6], in our NICU these patients
have become the target population for routinely initiating
probiotic prophylaxis with the product Lactobacillus
reuteri (L. reuteri) DSM 17938, available under the brand
name BioGaiaW(BioGaia, Sweden). Further reference to
Lactobacillus reuteri in this paper specifically refers to this
specific strain of L. Reuteri DSM 17938. This probiotic
was initially selected because of relative ease of adminis-
tration through nasogastric tubes without clogging the
tube, compared to other products during our own in vitro
experiments.
In this sequential analysis, our focus is to examine the
potential benefits of L. reuteri in the highest risk group,
neonates born≤ 1,000 grams. This population is typically
reported to have NEC rates of 10% [10].
Methods
Data collection
This study represents a retrospective chart review com-
paring the rates of NEC in neonates before introduction
of L. reuteri (January 2004 – June 2009), with routine
use of L. reuteri in neonates ≤ 1,500 gram birth weight
(July 2009 – April 2011). The use of L. reuteri as a
standard medicine in the <1500 gram infants in our
NICU was a unanimous decision of the neonatologists
and medical team at our institution, based on the sub-
stantial reduction in NEC rates seen in other studies
using probiotics in this manner [3-5]. As is our practice
when implementing new treatment strategies, we sought
to evaluate the impact of the change to prophylactic pro-
biotics, implemented in July 2009. The study to retro-
spectively review charts and measure outcomes wasapproved by the Institutional Review Board and
exempted from needing informed consent. The study fo-
cuses on extremely low birth weight (ELBW) neonates
born ≤ 1,000 grams, which is the highest at-risk group
for NEC [10]. Medical records for all neonates in our
NICU are routinely maintained in a unit-specific stan-
dardized database, NICU3W, which was designed and
maintained by one of the authors (MS). Patient data is
also categorized for reporting our NICU outcomes as
part of the Vermont Oxford reporting process. The hos-
pital electronic patient record was also used to collect
study data.
Neonates were only excluded from the analysis if they
died within the first week of life, as it was determined
that these patients would not have had the opportunity
to benefit from probiotic intervention. Data collected for
this study included: gender, gestational age (determined
by Ballard), birth weight, 5-minute Apgar score, growth
restriction, any antenatal corticosteroid administration,
method of delivery, maternal diagnosis of preeclampsia
or chorioamnionitis and diagnosis of NEC or late-onset
(after 7 days postnatal age) gram-negative bacteria or
fungal infection. NEC was categorized as medical (Bell
stage II NEC), surgical (Bell stage ≥3 NEC) or causing
death (all associated with Bell stage ≥3 NEC) [11,12].
Neonates diagnosed with NEC were categorized into
only one of the three groups (medical NEC, surgical
NEC or death attributed to NEC), despite the patients
who died all having surgical NEC as well.
Although the actual rates of breast feeding could not
be reliably collected, our sense was that breast feeding
practices were not overtly different during the period
studied in this analysis.
Probiotic administration, dosing and product selection
Starting in 2009, a probiotic in the form of L. reuteri,
available under the trade name BioGaiaW (BioGaia Inc.,
Lund, Sweden) was administered to preterm neonates.
Beginning in July 2009, L. reuteri was administered to
neonates once they crossed an empiric threshold for risk
of developing NEC. Thus, initiation of BioGaiaW was
often beyond the first 1–2 weeks of life. In 2010, this
practice was changed to empirically give BioGaiaW to all
neonates born≤ 1,500 grams once feedings were started,
almost exclusively within the first week of life, and con-
tinue administration until hospital discharge, as we have
had NEC occur in this population as late as 40 weeks
post-conception age.
According to the manufacturer of BioGaiaW, for term
neonates, the recommended daily dose is five drops
(approximately 0.18 mL given the oil-based nature of
the product drops). Five drops administers 100 million
live active L. reuteri cells. In our preterm neonates, we
opted to administer 0.1 mL as our standard dose.
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sterile conditions and refrigerated until administration
the same day. Administration was required within six
hours of removal from the refrigerator, per manufacturer
recommendation.
We selected BioGaiaW as our probiotic because the
manufacturer has demonstrated careful quality control
of the probiotic colonies delivered with their product.
The manufacturer quality control process is performed
at temperatures of 5, 25, and 30°C for 24 months, the
listed shelf life of the product. At each of these tempera-
tures, 5 drops of BioGaiaW, is guaranteed to deliver
1x108 colony forming units of L. reuteri (personal
communication, Eamonn Connolly PhD, Senior Vice
President Research, BioGaia AB, Stockholm, Sweden).
Additionally, other products examined in vitro, rou-
tinely clogged the orogastric tubes used in our neonates,
and this was not encountered with BioGaiaW.
Statistics
Statistical approaches used to examine this data include
unpaired t-test to examine differences in the demo-
graphic data collected before and after institution of Bio-
GaiaW. Statistically significant differences required
p < 0.05 between groups. Comparisons of the incidence
of NEC and late-onset infection for neonates not given
probiotic prophylaxis (January 2004 – June 2009) and
those routinely given prophylaxis with L. reuteri upon
initiation of feedings (July 2009 – April 2011), utilized
chi square analysis with Fisher exact t-test. Data is pre-
sented in yearly epochs to demonstrate the variability of
NEC and late-onset sepsis in this population. Because
the numbers of events are too small in yearly epochs to
detect even large effects, no statistical analysis is applied
to these data. We targeted a minimum of 80 neonates in
the pre- and post- Lactobacillus reuteri for a p < 0.05
and a power of 0.8, assuming a reduction of NEC from
15% to 2.5%.
Results
Patient demographics for included neonates born≤ 1,000
grams are listed across years in Table 1 (n = 311). Rates
of chorioamnionitis and small for gestational age neo-
nates were the only variables found to be statistically dif-
ferent between the pre- and post- routine L. reuteri
prophylaxis groups. Differences in NEC rates for SGA
neonates and non-SGA neonates (7.4 versus 13.8%,
p= 0.129) and for neonates of mothers diagnosed with
chorioamnionitis and those not diagnosed with chor-
ioamnionitis (15.1 versus 10.8%, p= 0.295) were not sta-
tistically significant.
The incidence of NEC and late-onset gram-negative
bacteria or fungal infection in yearly epochs is summar-
ized in Table 2. Comparison of events for the combinedyears before introduction of L. reuteri (January 2004 –
June 2009), with the years of L. reuteri prophylaxis (July
2009 – April 2011), showed statistically significant lower
rates of NEC (15.1 (35 of 232) versus 2.5 (2 of 79) %,
p = 0.0475) after routine L. reuteri prophylaxis was
started. A general decline in late-onset gram-negative
bacterial or fungal infections was observed (31 (72 of
232) versus 22.8 (19 of 79) %), but was not statistically
significant (p = 0.1112). The differences seen result in a
number needed to treat (NNT) of 8 to prevent one case
of NEC. Further, the lack of statistically significant bene-
fit for prevention of gram-negative or fungal infections
needs further study, since the current lack of statistical
significance may miss a number needed to treat benefit
as low as 12 to prevent one neonate from getting a
gram-negative or fungal infection.
The pattern of NEC prevention may also be important.
As noted in Table 2, the rates of medical NEC and pos-
sibly fatal NEC appear more benefited than surgical
NEC, although the numbers are too small to state this
with confidence. The NEC cases associated with only
medical treatment (antibiotics and restriction of oral
feedings for at least two weeks) occurred in 16 (6.9%)
neonates before instituting L. reuteri and none after in-
stituting routine L. reuteri prophylaxis. This difference is
statistically significant (p= 0.0143). Additionally, the
combined effect of surgical NEC and fatal NEC (which
are surgical cases), were reduced from pre- to post-
introduction of L. reuteri (8.2 versus 2.5%). This differ-
ence is not statistically significant (p= 0.1774).
No adverse events or infections related to L. reuteri
administration were noted in any of the infants included
in the analysis.
Discussion
Recent data from the Cochrane group have supported
routine use of probiotics for prevention of severe NEC
and all cause mortality in premature neonates born≤ 1,500
grams [6]. While this population does not exclude infants
born≤ 1,000 grams, those authors caution against routine
use of prophylactic probiotics in this high risk group until
more data is published on their benefits and potential ad-
verse effects [6]. In our NICU, the team elected to imple-
ment probiotics as a NEC prevention strategy. As part of
our quality improvement initiative we elected to measure
the impact of this strategy in the subpopulation of neo-
nates born≤ 1,000 grams who are at highest risk for devel-
oping NEC.10 We found this to be an effective strategy in
contributing to reduced NEC rates in our ELBW popula-
tion (15.1% to 2.5%). This effect is larger than seen in the
studies for neonates with birth weight below 1500 grams,
reported in the meta-analysis by Deshpande et al. [7] as
decreasing from 6.56% in controls to 2.37% in probiotic-
treated patients.







Male, % 48 49
GA (weeks), mean [SD] 26 [2] 26 [2]
BW (grams), mean [SD] 754 [151] 743 [175]
5-min Apgar, median [range] 7 [0–9] 7 [1-9]
Preeclampsia, % 26 25
Antenatal Steroids, % 95 95
Chorioamnionitis, % 53 36*
Cesarean Section, % 72 78
SGA, % 25 44*
Legend: GA, gestational age; SD, standard deviation; BW, birth weight; SGA,
small for gestational age.
*p < 0.05.
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born≤ 1,000 grams is starting to be published. The first
study exclusively evaluating probiotics in ELBW infants
[13] did not find a difference in NEC rates, 4/51 (7.8%)
in controls versus 3/50 (6%) in those receiving probio-
tics. This is likely in part due to inadequate power;
however, their results do support safety of administering
500 million colony forming units (CFU) of Lactobacillus
GG and 500 million CFU Bifidobacterium infantis once
daily to their ELBW neonates. One caveat is that our
experience with a lactobacillus GG product during our
in vitro experiments was that it frequently clogged the
nasogastric tube and would thus likely fail to be admi-
nistered in a reliable manner. This could positively
affect safety and negatively affect benefit results in a
study. As previously stated, the larger published pro-
biotic trials in neonates born≤ 1,500 grams did not ex-
clude neonates born≤ 1,000 grams. In Lin and
colleagues 2008 multicenter study evaluating Lactobacil-
lus acidophilus and Bifidobactrium bifidum, presenta-
tion of their results by birth weight allows the reader to
evaluate NEC rates in neonates born≤ 1,000 grams,
even though the study is not exclusive to this popula-
tion. Their NEC rates in neonates born≤ 1,000 grams









Med NEC, No. (%) 4 (7.5) 2 (8) 4 (8.3) 1
Surg NEC, No. (%) 3 (5.7) 1 (4) 3 (6.3) 1
NEC-related death, No. (%) 2 (3.8) 1 (4) 1 (2.1) 1
Total NEC, % 17 16 16.7 6
Infection, No. (%) 16 (30.2) 4 (16) 20 (42.7) 17
# Patients treated routinely with prophylactic Lactobacillus reuteri DSM 17938.4/102 (3.9%) in the group that received L. acidophilus
and B. bifidum (NNT=20, p =0.2245).3 The rate of
NEC in our pre-L. reuteri control group was highly vari-
able, ranging from 6.1% to 20.5%, and mostly ranging
from 16% to 20%, with the average for the total population
being 15.1%. This is higher than rates seen in other studies
reporting neonates below 1000 gram birth weight, which
are typically around 10% [14,15] and was a motivation to
seek interventions that could improve the results. The
dramatic improvement following introduction of L. reuteri
lowered NEC rates below those seen in any NICU reports.
In this particularly high-risk population, our progress is
not likely to be a coincidence since the cycle of change
has now affected 3 different epochs in our longitudinal
study (Table 2).
Another related question is whether practice changes
might account for the improved NEC rates. Against this is
that rates of NEC were similar until L. reuteri was intro-
duced and then remained similarly reduced after L. reuteri
was made standard practice. Since our group tends to
have similar practices and strives for continuity between
attending physicians, and the same physician group have
all been together throughout this study we cannot identify
other practice variables that caused the changed NEC
rates. We also did not make any other practice changes
starting in 2009, such as increased breast milk usage or a
different feeding strategy that we could identify to account
for this improved NEC rate.
Neurodevelopmental consequences (cerebral palsy,
cognitive impairment, visual impairment, hearing im-
pairment) are of major concern for infants who survive
NEC [16]. Infants born ≤ 1000 grams that develop NEC
requiring surgical intervention have much poorer neuro-
developmental outcomes than those with medical NEC
or no NEC [17]. In our analysis from July 2009 through
April 2011, elimination of medical NEC and NEC-
related death in ELBW neonates receiving L. reuteri
prophylaxis is remarkable.
Probiotics have been shown to be a barrier to bacterial
translocation and competitively exclude potential patho-
gens. Given these properties, one would conclude that
probiotics should also play a role in reducing rates of in-











n= 23 n=26 #
(2.3) 4 (10.3) 1 (2) 0 0 0
(2.3) 3 (7.7) 1 (2) 0 2 (5.6) 0
(2.3) 1 (2.6) 1 (2) 0 0 0
.8 20.5 6.1 0 5.6 0
(38.6) 13 (33.3) 2 (8.7) 6 (23) 7 (19.4) 6 (35.3)
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[3,4,13,18,19] we did not find a significant reduction in
incidence of culture-positive late-onset bacterial or fun-
gal infection (31 versus 22.8%). Perhaps, as other authors
have suggested, we have yet to understand the optimal
probiotic product, dose and duration to reach this infec-
tion prevention threshold.
We chose to dose our preterm neonates daily with
0.1 mL of L. reuteri. This dose was a conservative reduc-
tion of what the manufacturer recommends for term
infants. After two years of using this product, we wanted
to confirm that the product was colonizing the infant
gut in effective amounts. In 2011, we collected stool
samples at random from 7 infants who had been receiv-
ing L. reuteri for varying lengths of time (12 – 101 days)
and found that, while all 7 had some level of fecal
colonization, 3 of the 7 infants did not have optimum
fecal colonization (106 to 107 L. reuteri CFU/g stool). As
a result, our NICU decided to increase our standard
prophylaxis dose from 0.1 mL to 0.2 mL daily in order
to more accurately administer the recommended 100
million live, active L. reuteri cells. Outcomes from this
adjusted dose are currently being collected and are not
reported in the present study.
One of the major criticisms surrounding probiotic use
focuses on generalization of results to all probiotics
strains. Therefore, it cannot be assumed that our results
obtained with L. reuteri DSM 17938 can be extrapolated
to other probiotic products. Each individual preparation
must be analyzed separately in the context of other suc-
cessful NEC prevention strategies.
Although we do not completely understand the patho-
genesis of NEC, it is recognized that NEC involves mul-
tiple contributing factors unique to preterm infants.
Probiotics have been shown to assist in decreasing NEC
rates, but given the multi-factorial nature of the disease,
we would expect prevention to ultimately require a
multi-modal strategy as well.Conclusions
Prophylactic initiation of Lactobacillus reuteri as a pro-
biotic for prevention of NEC resulted in statistically sig-
nificant reduction in NEC. Our results support that 1
NEC case is avoided for every 8 cases given L. reuteri
prophylaxis. The benefits were especially focused on the
subsets of medical NEC and death related to NEC in
infants born ≤ 1000 grams. These results suggest a sig-
nificant benefit to L. reuteri prophylaxis in this subset of
neonates.
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